Drugs / Lymecyclin and corresponding placebos of the experimental arm
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05821478 Comparator | May 2025 → Feb 2027 expected | hidradenitis suppurativa | Institut Pasteur | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lymecyclin and corresponding placebos of the experimental arm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05821478 ↗ |
| Known as | Tetralysal | “12-week course of oral lymecycline (Tetralysal daily dose 452mg)” NCT05821478 ↗ |
| Route | Oral | “oral lymecycline” NCT05821478 ↗ |